Status: Not yet recruiting
A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma
SOT106 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called LRRC15, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT106, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.
Participants needed: 70
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: SOTIO Biotech a.s.Updated: Sep 3, 2026Locations: 1
Eligibility criteria
≥18 years of age and body weight of ≥30 kg on the day of signing the prescreenin... [+29]
Received radiation therapy ≤14 days before day 1 of cycle 1 or not recovered to... [+24]